0      0


3067 - HSK7653, a Novel Ultralong-Acting DPP-4 Inhibitor, as Monotherapy in Patients With Type 2 Diabetes—A Randomized, Double-Blind, Placebo-Controlled Phase III Trial


‐ Jun 23, 2023 3:15pm


Speaker(s):

You must be logged in and own this session in order to post comments.